

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4155

TITLE: Functional Analysis of Alpha-6 Integrin Cytoplasmic Domains

PRINCIPAL INVESTIGATOR:  
Dr. Susan Z. Domanico  
Dr. Vito Quaranta

CONTRACTING ORGANIZATION:  
The Scripps Research Institute  
La Jolla, California 92037


REPORT DATE:  
30 July 95

TYPE OF REPORT:  
Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.



19951003 041

DTIC QUALITY INSPECTED 5

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> 30 July 95	<b>3. REPORT TYPE AND DATES COVERED</b> Annual 1 Jul 94 - 30 Jun 95	
<b>4. TITLE AND SUBTITLE</b> Functional Analysis of Alpha-6 Integrin Cytoplasmic Domains			<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4155	
<b>6. AUTHOR(S)</b> Dr. Susan Z. Domanico Dr. Vito Quaranta				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> The Scripps Research Institute La Jolla, California 92037			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release, distribution unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b> The expression of different cytoplasmic domains could influence the function of the $\alpha 6 \beta 1$ laminin receptor integrin by affecting the ligand binding characteristics of the integrin or by altering the intracellular interactions between $\alpha 6$ and cytosolic components (i.e.- cytoskeleton or signaling molecules) thereby mediating unique cellular responses as a result of adhesion to the extracellular matrix. The goal of this proposal is to dissect the biological roles of the alternatively spliced cytoplasmic domains of $\alpha 6$ . To accomplish this I have established a panel of ES cells expressing human $\alpha 6A$ and $\alpha 6B$ . The ES- $\alpha 6A$ cells exhibit a unique morphology, characterized by the presence of cytoplasmic extensions and lamellipodia. In contrast, the ES- $\alpha 6B$ transfectants have the same morphology as wild type ES cells, growing in smooth-bordered islands. ES- $\alpha 6A$ cells showed a 10-fold increase in migration towards laminin, compared to ES and ES $\alpha 6B$ cells. When assayed using video microscopic techniques, ES- $\alpha 6A$ cells exhibited classical lamellipodia movement and are more motile than ES and ES $\alpha 6B$ cells. This suggests that the $\alpha 6A$ cytoplasmic domain interfaces with cytoplasmic molecules that direct migration.				
<b>14. SUBJECT TERMS</b> Laminin receptor, alpha6beta1, alternatively spliced cytoplasmic domains, migration			<b>15. NUMBER OF PAGES</b> 30	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

So Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

So In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

So In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

So In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

Susan Z. Domania 7/27/95  
PI - Signature Date

**TABLE OF CONTENTS**

	<b>PAGE</b>
Front cover	1
SF 298	2
Foreword	3
Table of contents	4
Introduction	5-8
Body	9-13
Conclusions	14-15
References	16-20
Appendix	21-30

## INTRODUCTION

Integrins are a widely expressed family of cell surface receptors (Hynes, 1987). This diverse family of transmembrane glycoproteins appears to be the major receptors by which cells attach to the ECM, and several integrins also mediate cell-cell interactions. Integrins are expressed as non-covalently associated heterodimers consisting of an  $\alpha$  and a  $\beta$  subunit. The integrin extracellular domains form a ligand-binding site recognizing one or more extracellular ligands or counter-receptors on other cells. To date, in vertebrates, 14  $\alpha$  and 8  $\beta$  subunits have been identified. Although these could combine to produce more than 100 heterodimers, the actual diversity is much more restricted and currently only 20 different receptors have been identified. Many  $\alpha$  subunits associate with only one  $\beta$  subunit, however, there are a few exceptions, such as  $\alpha 4$ ,  $\alpha 6$ , and  $\alpha v$ , which associate with more than one  $\beta$  subunit resulting in more diverse ligand associations. Additionally there are several instances of alternatively spliced domains existing in  $\alpha 3$ ,  $\alpha 6$ ,  $\alpha 7$  and  $\beta 4$  (Hynes, 1992; Collo et al., 1993). The potential for diversity in this receptor family is therefore quite large.

Integrins play a fundamental role during the entire life of an organism. As one example, early in embryo development, fibronectin receptors are thought to play a crucial role in mesoderm migration (Elices et al., 1991). In fact when the  $\alpha 5$  or  $\alpha 4$  subunits are disrupted, mouse embryos die early in gestation (Yang et al., 1995; Yang et al., 1993). In normal adult physiology, integrins play varied roles, from the establishment of hemidesmosomes in keratinocytes to facilitate wound healing (Kuropakus et al., 1991), to the binding of soluble fibronectin by platelets to initiate clot formation (Hynes, 1987). Additionally, integrins may play a role in disease states, such as cancer, where modulation of integrin expression may play a crucial role in metastasis (Mareel et al., 1992).

Cell adhesion plays a key role in tumor progression and metastasis. In order to invade and metastasize, tumor cells must acquire the ability to detach from the primary site, cross basement membranes, migrate, traverse vessel walls and reattach in a new site. Cell adhesion molecules, such as integrins, must play key roles in all of these steps. Recent publications have suggested that integrins may be considered tumor associated antigens given their apparent deregulation in various types of tumors (Miettinen et al., 1993). Altered expression or function of integrins may directly influence the ability of a tumor cell to detect basement membrane boundaries and/or confer novel attachment and invasive properties.

A substantial body of literature currently documents altered or deregulated integrin expression in tumor cells (Koukoulis et al., 1991;

Carey et al., 1992; Lin et al., 1993; Ruiz et al., 1993; Sager et al., 1993). The integrins  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$  bind isoforms of the extracellular matrix protein laminin and exhibit altered expression patterns in tumor cells as compared to normal tissue. In particular, altered patterns of  $\alpha 6$  integrins expression have been documented in breast cancer (Koukoulis et al., 1991), squamous cell cancer of the head and neck (Carey et al., 1992), and fibrosarcomas (Lin et al., 1993). In separate studies, antibodies specific for  $\alpha 6$  suppressed mouse melanoma metastasis (Ruiz et al., 1993). Additionally,  $\alpha 6$  has been identified as a potential tumor suppresser gene. Using the differential display method of differential expression cloning, Sager et al. (Sager et al., 1993) detected loss of  $\alpha 6$  expression in metastatic breast tumor cells and low expression in primary breast tumor cells, compared to normal mammary epithelial cells. Concurrent with  $\alpha 6$  as a tumor suppresser, Gui et al. (Gui et al., 1995) show that loss of  $\alpha 6$  expression correlates with the presence of axillary metastasis in breast cancer. In direct opposition, however, Friedrichs et al. (Friedrichs et al., 1995) show that high expression of  $\alpha 6$  is correlated with reduced survival of breast cancer patients. Although all of these results are compelling, a simple overview of these and other current data, however, establishes that there is no consistent trend towards gain or loss of  $\alpha 6$  integrins expression and tumor cell metastasis or cancer progression. Instead, it is clear that we must understand the function of  $\alpha 6$  integrins before we can define their role in cancer progression. The studies supported by this proposal will dissect the specific contributions of the  $\alpha 6A$  and  $\alpha 6B$  isoforms to integrin function, will further define the mechanisms by which cells respond to the ECM, and ultimately will help interpret the relevance of altered integrin expression on tumor cells. This information could be used to develop rational therapeutics for breast cancer treatments.

Just as the extracellular domain mediates specific matrix contacts, the short (less than 50 amino acids) cytoplasmic domains of integrins have been shown to mediate specific intracellular interactions. Integrins function as a transmembrane link between the ECM and the interior of the cell. There is evidence that some integrins associate with components of the microfilament system, possibly through a connection with talin, vinculin, or  $\alpha$ -actinin. This interaction results in the localization of integrins, *in vitro*, in focal adhesion contacts (Burrige et al., 1988). More specifically, deletion of all or part of the  $\beta 1$  cytoplasmic domain interferes with integrin associations in focal contacts (Solowska et al., 1989; Hayashi et al., 1990; Marcantonio et al., 1990). Evidence of  $\alpha$  subunit interactions with the cytoskeleton is less direct, however the unique cytoplasmic domains of  $\alpha$  subunits appear to direct cytoskeleton associations and the cytoplasmic domains of different integrins may

mediate different contacts. This has been demonstrated in the example where  $\alpha 5\beta 1$  localizes to focal adhesion contacts, while  $\alpha 3\beta 1$  does not, although both are fibronectin receptors and share identical  $\beta$  subunits (Elices et al., 1991). Additionally, different  $\alpha$  subunit cytoplasmic domains have been shown to mediate distinct cellular functions such as collagen gel contraction or cell migration (Chan et al., 1992). Clearly, given the diversity among subunit cytoplasmic domains and the existence of alternatively spliced cytoplasmic domains (Tamura et al., 1991; Cooper et al., 1991), multiple opportunities are possible for a subunits to direct unique cellular responses to identical ECM ligands.

The  $\alpha 6$  integrin subunit can associate with one of two  $\beta$  subunits,  $\beta 1$  and  $\beta 4$  (Tamura et al., 1991; Hemler et al., 1988). The  $\alpha 6\beta 1$  heterodimer has been shown to function as a laminin receptor (Cooper et al., 1991; Sonnenberg et al., 1988) and is expressed on cells of myeloid, lymphoid, and epithelial origin, as well as other cell types (Sonnenberg et al., 1990). The  $\alpha 6\beta 4$  heterodimer is expressed in a more restricted pattern. It is detected on various epithelial cells, endothelia, and peripheral nerves (Jones et al., 1991; Quaranta and Jones, 1991). Recent data suggest that  $\alpha 6$  integrins may mediate cell-cell interactions in addition to cell-ECM binding. The monoclonal antibody EA-1, which specifically recognizes  $\alpha 6$ , has been shown to block melanoma cell binding to endothelial cells (Ruiz et al., 1993). To date, the cellular ligand is unknown, and it is possible that cell-cell interactions are the result of activation of the  $\alpha 6$  integrin.

Two variants of the  $\alpha 6$  integrin subunit,  $\alpha 6A$  and  $\alpha 6B$ , have been identified in Dr. Quaranta's laboratory (Cooper et al., 1991; Tamura et al., 1991). These variants differ in the structure of their cytoplasmic tails and appear to arise from alternative mRNA splicing. The cytoplasmic domain of  $\alpha 6A$  is 36 amino acids in length, the cytoplasmic domain of  $\alpha 6B$  is 54 amino acids in length and the two domains share little homology. This proposal represents an approach to define the functional roles of the alternatively spliced cytoplasmic domains of the integrin subunit  $\alpha 6$ .

Mouse embryonic stem (ES) cells express only  $\alpha 6B$  in the undifferentiated state, then begin to express  $\alpha 6A$  upon differentiation (Cooper et al., 1991). We extended studies on this developmental regulation of  $\alpha 6$  isoform expression by following  $\alpha 6A$  expression in the developing mouse embryo (Collo et al., 1995). Using PCR and immunohistochemistry, we determined that the embryo exclusively expresses  $\alpha 6B$  until 8 days of gestation. At this point,  $\alpha 6A$  is only expressed in the developing heart. As the heart develops,  $\alpha 6A$  is expressed in a gradient in the myocardium.  $\alpha 6A$  expression parallels the development of trabeculae in the heart. We postulated that  $\alpha 6A$  may mediate a more migratory phenotype, as it appears that these cells are migrating towards the inner chambers of the developing heart tube. This

distinct regulation of expression suggests that the A and B isoforms may be exploited by different cell types to regulate the cellular response to laminin binding.

The regulation of adhesiveness of the  $\alpha 6$  integrin may be intrinsic, in that the conformation of the cytoplasmic domain directly alters the binding affinity of the extracellular domain. An additional possibility, however, is that the different cytoplasmic domains of  $\alpha 6$  interact with unique subsets of cytoplasmic adapter molecules that regulate adhesiveness of the receptor. The diversity of response could be expanded further if the adapter molecules are cell-type specific or developmentally regulated to coordinately influence the function of the integrin. The expression of alternative cytoplasmic domains also may function to couple identical adhesion events to unique cellular responses. In this regard, subunit and cell-type specific cytoplasmic adapter proteins may couple adhesion to distinct cellular responses, thereby increasing functional flexibility in response to binding an identical ECM component. I have begun to address these hypotheses with the model system presented in this proposal. I have established a panel of ES cells expressing human  $\alpha 6A$  and  $\alpha 6B$ . Although there is no detectable difference in adhesion to laminin, the ES- $\alpha 6A$  cells exhibit a unique morphology, with more cytoplasmic extensions, and the ES- $\alpha 6A$  cells show a 10-fold increase in migration towards laminin. This suggests that the  $\alpha 6A$  cytoplasmic domain interfaces with cytoplasmic molecules that direct migration.

## BODY

When developing a model system to study the function of the  $\alpha 6A$  and  $\alpha 6B$  tails, it would be helpful to utilize a cell line for transfection that does not express the  $\alpha 6$  integrin. However, since we hypothesize that the cytoplasmic tails interact with cytoplasmic factors that may link the integrin to downstream events, we would like to use a cell line that contains all the necessary "co-factors". Therefore, the approach I have taken is to selectively delete the  $\alpha 6$  gene product from a cell that normally expresses the integrin. Unlike the approach taken by Shaw and Mercurio (Shaw and Mercurio, 1994) and Delwel et al. (Delwel et al., 1993), using a mutated ES cell line will allow for reconstitution with various  $\alpha 6$  constructs in a "normal" background. Indeed, since differentiated ES cells normally switch to express  $\alpha 6A$ , I will be able to probe for both  $\alpha 6B$  specific and  $\alpha 6A$  specific effector molecules simply by allowing the transfected cells to differentiate.

Substantial effort has been expended toward the goal of producing an  $\alpha 6$  null ES cell, as detailed in Aim 2 of this proposal. The vector p244 shown in Fig 1 has been used for transfection into ES cells using electroporation. Briefly,  $1 \times 10^7$  cells were washed with electroporation buffer. Linearized DNA (20  $\mu$ g) was mixed with the cells on ice, then the cells were subjected to electroporation using a BioRad gene pulser, 0.5 kvolt, 250  $\mu$ Farads. After 10 min on ice, the cells were transferred to plating media. Twenty-four hours later, cells were selected in media containing 300  $\mu$ g/ml G418 and 2  $\mu$ M gancyclovir. Approximately 14 days post transfection, single colonies were picked and disaggregated in trypsin. Duplicate plates were grown. One plate was harvested to prepare genomic DNA for screening by PCR using the methods described by Laird et al. (Laird et al., 1991). PCR was performed on DNA prepared from pools of 8 clones using primer C in the neo gene and primer B in the native  $\alpha 6$  gene (Fig 1A). The PCR products were run on an agarose gel, transferred to nylon, and probed with oligo E that had been end labeled with  $^{32}P$ . This procedure identified positive PCR products in reactions using p209 as a control (Fig 1B). A total of 7 transfections were performed and 1852 colonies were screened using this procedure. Although 5 potential "light" positives were identified, when they were expanded and analyzed as single clones, all were negative for homologous recombination. As stated in my proposal, since this vector did not yield cells with targeted mutations within a reasonable time frame, I have begun construction of a new targeting vector that will be created with DNA isogenic to the ES cells and will be designed to disrupt the exon containing the ATG of  $\alpha 6$ . To that

end, I have screened a 129 mouse genomic library (Stratagene) and I have characterized several clones at the DNA level. One clone has been subcloned and is being screened by sequencing to define the intron/exon boundaries that are present. I anticipate having a new targeting vector by October, 1995.

In accordance with Aim 1, I have established a quantitative adhesion assay using the ES-1 cells. This assay was performed essentially as described by Calof and Lander (Calof and Lander, 1991) and represents a major technical departure from standard adhesion assays as described by Cooper et al. (Cooper et al., 1991) or Shaw et al., (Shaw et al., 1993), which are used predominantly in the field. The most prominent advantages are as follows: 1. Contact between the cells and the substrata is synchronized by centrifugation. This is relevant, since cells may settle at varying rates when simple gravitational sedimentation is employed. Additionally, centrifugation decreases the incubation time, which is important when analysis is performed on cells that are capable of depositing their own matrix. 2. The geometry of the custom assay plate decreases the occurrence of background due to non-receptor mediated trapping in the edges of the flat-bottomed wells usually employed. In the proposed assay, the gasket creating the cell wells is removed before samples are quantified, thereby removing the potential for artifacts. 3. Centrifugation is used to remove non-adherent cells. This technique potentially allows the added dimension of varying centrifugation force to assay degrees of binding as compared to standard assays, which simply wash away non-adherent cells with buffer. 4. Washing steps are replaced with immersion of the plate in buffer, thereby eliminating inconsistencies in washing conditions.

An example of the optimized assay is shown in Fig 2. The wells of the assay plate were coated with a titration of EHS laminin or bovine fibronectin, incubated at 37°C for 4 hrs, washed, and blocked with a BSA solution. <sup>35</sup>S-methionine-labeled ES cells were introduced into the wells at a concentration of 50,000 cells/well. The plates were sealed and immediately centrifuged at 600 rpm to synchronize cell contact with the substratum. The cells were allowed to bind for 30 min at 37°C, then the plates were flooded with warm PBS, sealed, inverted and centrifuged for 8 minutes at 800 rpm. The entire plate, still inverted, was submerged in cold PBS and then in fixative (3.7% formaldehyde / 5% sucrose / 0.1% Triton X 100 /PBS). After air-drying, the bound radioactivity, representing cell adhesion, was quantified on a Molecular Dynamics phosphorimager. Non-specific background was measured by cell binding to BSA coated plates, and was essentially zero. The laminin concentration chosen for all future experiments was 40 µg/ml.

Since  $\alpha 6$  null ES cells were not available yet, preliminary

transfection experiments were begun using wildtype cells. Full length  $\alpha 6A$  or  $\alpha 6B$  was subcloned into the expression vector pBJneo.  $\alpha 6$  expression was driven by the  $SR\alpha$  promoter (Takebe et al., 1988), composed of the SV40 early promoter and the R-U5 region from the long terminal repeat of human T-cell leukemia virus type 1. Electroporation conditions were performed as described above. After approximately 14 days of selection in G418, colonies were harvested in bulk, expanded, and cells were prepared for fluorescence activated cell sorting (FACS). The monoclonal antibody BQ16 was used to detect transfectants. BQ16 specifically recognizes human  $\alpha 6$ , with no binding to untransfected, mouse, ES-1 cells. Positive cells were sorted, expanded, and further experiments were performed on the bulk positive population. Fig 3 shows that the two cell lines chosen for analysis, ES6A.5 and ES6B.1, express similar levels of human  $\alpha 6$ , as detected by BQ16 binding. As control, ES-1 cells exhibit no binding to BQ16.

To further characterize the transfectants, detergent lysates were prepared for western analysis. Briefly, cells were trypsinized, blocked with trypsin inhibitor, washed, and lysed in 2% Renex in PBS with 0.174  $\mu\text{g/ml}$  PMSF, 0.7  $\mu\text{g/ml}$  pepstatin A, 0.5  $\mu\text{g/ml}$  leupeptin and 2  $\mu\text{g/ml}$  aprotinin. Lysates were incubated on ice for 1 hr, then centrifuged at 40,000 rpm for 1 hr. Lysates were separated on 4-20% SDS-PAGE gradient gels (Novex, San Diego, CA) under reducing and non-reducing conditions and then transferred to PVDF (Millipore, Bedford, MA). Expression of the transfected  $\alpha 6A$  was detected using a polyclonal antibody raised against the cytoplasmic tail of  $\alpha 6A$  (6845) which has been affinity purified on an  $\alpha 6A$  peptide column (Collo et al., 1995). The 6845 antibody does not detect any protein in untransfected ES-1 cells (Cooper et al., 1991), therefore the 140 kD band detected in Fig. 4 is human  $\alpha 6A$ . Similar western blots were performed on ES6B.1 using a polyclonal antibody against the  $\alpha 6B$  cytoplasmic tail. There was significant background with this antibody (data not shown) and I am currently performing affinity purification to optimize the results.

The initial question addressed, using the transfected cells, was whether adhesion to laminin was altered when  $\alpha 6A$  was expressed in a cell that normally expressed  $\alpha 6B$ . Since ES-1 cells normally expressed  $\alpha 6B \beta 1$ , it was not expected that we could assay differences in adhesion mediated solely by the  $\alpha 6A$  or  $\alpha 6B$  molecules. Indeed, as shown in Fig 5, both ES6A.5 and ES6B.1 cells bind EHS laminin to the same degree as ES-1 cells. These studies are not complete. It is possible that expression of  $\alpha 6A$  will alter the degree of adhesiveness. To address this, I will take advantage of the design of this adhesion assay and subject the panel of cells to different G forces, by increasing the rpm used to remove nonadherent cells after adhesion. This will determine whether  $\alpha 6A$  and

$\alpha$ 6B contribute differently to the "strength of adhesion". I am also initiating experiments to compare cell adhesion to isoforms of laminin. Our lab has purified and is characterizing the laminin isoform, laminin 5r ( $\alpha$ 3,  $\beta$ 3,  $\gamma$ 2),. Therefore I will extend these studies to include laminin 5r. Fig 5 shows a preliminary experiment in which ES-1 cells bind laminin 5r. I will continue this work and assay the transfected cells for 1) adhesion and 2.) strength of adhesion.

ES-1 cells are a subline isolated by Dr. Helen Cooper (Cooper et al., 1991) by growing D3 ES cells without a fibroblast feeder layer in the presence of leukemic inhibitory factor (LIF) on tissue culture plates coated with denatured gelatin. In this system, ES-1 cells exhibit the same morphology as other ES lines. In particular, the cells grow in islands and have very smooth borders. During normal passage, it became evident that the ES6A.5 cells had a significantly different morphology. Unlike the ES-1 and ES6B.1 cells, ES6A.5 cells had many cytoplasmic extensions and did not maintain small islands of smooth colonies. Fig 6 shows a comparison of ES-1, ES6B.1 and ES6A.5 cells grown on gelatin. The same differences in morphology were also seen when the cells were grown on laminin.

As proposed in Aim 1, it was possible that the  $\alpha$ 6A and  $\alpha$ 6B isoforms confer different levels of motility to the cell. To address this question, two types of migration assays were performed. Preliminary experiments monitored cell motility on glass coverslips coated with EHS laminin. ES-1, ES6A.5 or ES6B.1 cells were centrifuged onto coated coverslips and immediately transferred to a microscope with a heated stage equipped with video-tracking equipment. A field of cells was monitored for 2 hrs. Analysis of the condensed 2 hrs showed that the ES6A.5 cells extended more pseudopodia and moved approximately 3 microns, compared to ES-1 and ES6B.1 cells which moved only approximately 1 micron (data not shown). These experiments will be expanded further to cover longer times (8hrs) to directly quantify the distance migrated for all cell types.

The second migration assay performed utilized Transwell chambers (Costar, Cambridge, MA). These chambers have polycarbonate filters with 8 micron pores. Matrix molecules were coated on the bottom side of the filters and cells were plated on the upper side of the filters. After an 18 hr incubation at 37°C, the cells on the membrane were fixed and the top of the membrane was swabbed to remove cells that had not migrated towards the matrix. For quantitation, the filters were cut out of the chamber, mounted on slides, and stained cells were counted using a 40x objective. Fig 7 shows that ES6A.5 cells exhibit significantly higher migration towards EHS laminin than ES-1 or ES6B.1.

Interestingly, ES6A.5 cells also migrated well on fibronectin. Several explanations could address this result. An intriguing possibility

was that expression of  $\alpha 6A$  cross-activated the fibronectin receptor. If this were the case, the migration would be inhibited by the peptide "RGD". It has been clearly shown that "RGD" disrupts integrin binding to fibronectin (Cheresh, 1991). To address this hypothesis, the transwell assay was performed in the presence and absence of 268  $\mu M$  RGD peptide (Barker et al., 1992). As a control for RGD inhibition, M21 cells (Felding-Habermann et al., 1992) were included. Fig 8 shows that RGD did not significantly inhibit ES6A.5 migration towards fibronectin, while the M21 cells were completely inhibited. This suggested that the ES6A.5 cells were not using their fibronectin receptor to migrate through the filter. A more likely explanation for the increase in ES6A.5 migration on fibronectin was that the ES6A.5 cells deposited their own laminin and used this newly synthesized matrix for migration. A direct test of this will be to block the migration with an antibody directed against  $\alpha 6$ . The experiments using GoH3 (Sonnenberg et al., 1986) to block  $\alpha 6$  mediated migration are currently being performed. In support of the hypothesis that cells are migrating on matrix they are secreting, Fig 9 shows that ES6A.5 cells migrate to a small degree on membranes coated with gelatin or membranes simply incubated with HBSS (data not shown). Experiments are currently being performed to directly assay for laminin deposited by the cells using western blots and immunofluorescence. Comparison of the assays using gelatin or uncoated membranes for migration to migration on fibronectin showed that ES6A.5 cells still migrated to a greater degree if fibronectin is present. Future experiments will survey other matrices to determine which proteins support increased migration. Interpreting the mechanism of increased migration will be pursued over the next several months. The exciting preliminary conclusion of this work is that the expression of  $\alpha 6A$  in a cell that normally expresses  $\alpha 6B$  confers a novel migratory phenotype. This is an important milestone in defining the functional differences between the  $\alpha 6A$  and  $\alpha 6B$  cytoplasmic tails.

## CONCLUSIONS

In summary, using ES cells transfected with human  $\alpha 6A$  or  $\alpha 6B$ , I have shown that the  $\alpha 6A$  integrin subunit conferred a migratory phenotype. This was shown both by tracking motility on laminin-coated coverslips with video microscopy and also by cell migration through a membrane towards laminin. Additionally, the ES6A.5 cells exhibit a novel morphology. The cells have more cytoplasmic extensions and extend lamellipodia compared to untransfected ES-1 cells and ES6B.1 cells. This is an important finding towards the goal of this proposal of understanding the functional differences between the  $\alpha 6A$  and  $\alpha 6B$  cytoplasmic tails of the  $\alpha 6\beta 1$  laminin receptor.

This finding is of great importance to the continuation of this grant at several levels. First, it shows that significant findings can be generated using wild type ES cells as a model system to analyze the function of the alternative cytoplasmic domains of the  $\alpha 6$  integrin. Although this is true, these findings may be extended further if the  $\alpha 6$ -null cell is available. For that reason, I plan to continue my efforts towards generating the  $\alpha 6$ -null ES cell line. Second, the current findings will serve as an assay by which I can analyze the effect of mutations imposed on the  $\alpha 6$  cytoplasmic domain. Aim 3 of the original proposal outlined a series of experiments designed to map regions of the cytoplasmic tail that confer particular functions to the integrin. Using migration as a test for gain/loss of function, I may be able to define specific amino acid sequences that are required for migration. Finally, this panel of cell lines will open the door for additional experiments that were not originally proposed, but would expand our understanding of the function of the cytoplasmic domains of  $\alpha 6$ .

The new experiments I plan to perform are designed to address the question of whether the cytoplasmic domains interact with cytoplasmic molecules and if there are differences between the molecules that interact with  $\alpha 6A$  or  $\alpha 6B$ . Recent data have expanded the view of the function of integrin receptors. In addition to serving as adhesion molecules and contacts to cytoskeleton, integrins have been shown to function as signaling receptors that intersect with other signaling pathways in the cell (Schwartz, 1992; Juliano and Haskill, 1993). After engagement with ligand, integrins transduce signals that affect gene expression, tyrosine phosphorylation, and levels of intracellular pH or calcium (Schwartz, 1992). The biochemical pathways and specific second messenger molecules involved in this signal transduction are just beginning to be elucidated, however one prominent association has been documented between the platelet integrin  $\alpha IIb \beta 3$  and focal adhesion kinase (pp125<sup>FAK</sup>) (Lipfert et al., 1992; Zachary and Rozengurt, 1992). In fact, preliminary evidence suggests that  $\alpha 6$  interacts with signaling

molecules. Gimond et al. (Gimond et al., 1995) showed that the  $\alpha 6A$  tail can be phosphorylated *in vitro* by protein kinase C. Additionally, de Curtis and Gatti (de Curtis and Gatti, 1994) showed that  $\alpha 6$  can be isolated in a large complex on sucrose gradients, although the proteins associated have not been characterized. I propose to use the methods of Plopper et al. (Plopper et al., 1995) to isolate  $\alpha 6A$  and  $\alpha 6B$  integrin associated complexes after engagement of the receptor by EHS laminin, laminin 5r or anti-human  $\alpha 6$  antibodies. We will perform *in vitro* kinase assays to determine if any kinase molecules are associated with the complexes. Additionally we will perform western blot analysis to probe for the presence of known signaling molecules in the complex. The hypothesis is that there will be some known molecules associated with the integrin complex and that this profile may be different between the  $\alpha 6A$  and  $\alpha 6B$  isoforms.

In summary, during the first year of funding for this grant, significant progress has been made towards the achievement of all 4 aims. Although the  $\alpha 6$ -null cell has not been obtained, new efforts are being designed and implemented to obtain that cell line. The quantitative adhesion and migration assays have been optimized for ES cells. Most importantly, a panel of transfected cell lines has been created using wild type ES cells as a host. Although the parental cells express mouse  $\alpha 6B$ , a novel finding, namely that  $\alpha 6A$  confers a migratory phenotype on ES cells, has been described. This finding has validated the use of this model system and will allow the pursuit of aims 3 and 4, as well as experiments designed to identify cytoplasmic molecules interacting with the  $\alpha 6A$  and  $\alpha 6B$  cytoplasmic domains. Understanding the function of the  $\alpha 6$  integrin subunit will be of paramount importance to our understanding of development and in the understanding of carcinogenesis.

**REFERENCES**

- Barker, P.L., Bullens, S., Bunting, S., Burdick, D.J., Chan, K.S., Deisher, T., Gadek, T.R., Gantzog, R., Lipari, M.T., and et al., (1992). Cyclic RGD peptide analogues as antiplatelet antithrombotics. *Journal of Medicinal Chemistry* **35**, 2040-2048.
- Burridge, K., Fath, K., Kelly, T., Nuckolls, G., and Turner, C. (1988). Focal adhesions: Transmembrane junctions between the extracellular matrix and the cytoskeleton. *Ann. Rev. Cell Biol.* **4**, 487-525.
- Calof, A.L. and Lander, A.D. (1991). Relationship between neuronal migration and cell-substratum adhesion: laminin and merosin promote olfactory neuronal migration but are anti-adhesive. *J. Cell. Biol.* **115**, 779-794.
- Carey, T.E., Laurikainen, L., Nair, T.S., Reinke, T.S., Coling, D.E., Wolf, G.T., Van Waes, C., Liebert, M., and Marcelo, C. (1992). Regulation of expression and phosphorylation of A9/alpha 6 beta integrin in normal and neoplastic keratinocytes. *Monogr. Natl. Cancer Inst.* **13**, 75-86.
- Chan, B.M., Kassner, P.D., Schiro, J.A., Byers, H.R., Kupper, T.S., and Hemler, M.E. (1992). Distinct cellular functions mediated by different VLA integrin alpha subunit cytoplasmic domains. *Cell* **68**, 1051-1060.
- Cheresh, D.A. (1991). Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. [Review]. *Cancer & Metastasis Reviews* **10**, 3-10.
- Collo, G., Starr, L., and Quaranta, V. (1993). A new isoform of the laminin receptor integrin alpha7beta1 is developmentally regulated in skeletal muscle. *J. Biol. Chem.* **268**, 19019-19024.
- Collo, G., Domanico, S., Klier, G., and Quaranta, V. (1995). Gradient of integrin  $\alpha$ 6A distribution in the myocardium during early heart development. *Cell Adhes. Commun.* **3**, 101-113.
- Cooper, H.M., Tamura, R.N., and Quaranta, V. (1991). The major laminin receptor of mouse embryonic stem cells is a novel isoform of the  $\alpha$ 6 $\beta$ 1 integrin. *J. Cell Biol.* **115**, 843-850.
- de Curtis, I. and Gatti, G. (1994). Identification of a large complex containing the integrin alpha 6 beta 1 laminin receptor in neural retinal cells. *Journal of Cell Science* **107**, 3165-3172.

Delwel, G.O., Hogervorst, F., Kuikman, I., Paulsson, M., Timpl, R., and Sonnenberg A., (1993). Expression and function of the cytoplasmic variants of the integrin alpha 6 subunit in transfected K562 cells. Activation-dependent adhesion and interaction with isoforms of laminin. *Journal of Biological Chemistry* *268*, 25865-25875.

Elices, M.J., Urry, L.A., and Hemler, M.E. (1991). Receptor functions for the integrin VLA-3: fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. *J. Cell. Biol.* *112*, 169-181.

Felding-Habermann, B., Mueller, B.M., Romerdahl, C.A., and Cheresh, D.A. (1992). Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. *Journal of Clinical Investigation* *89*, 2018-2022.

Friedrichs, K., Ruiz, P., Franke, F., Gille, I., Terpe, H.J., and Imhof, B.A. (1995). High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. *Cancer Research* *55*, 901-906.

Gimond, C., de Melker, A., Aumailley, M., and Sonnenberg, A. (1995). The cytoplasmic domain of alpha 6A integrin subunit is an in vitro substrate for protein kinase C. *Experimental Cell Research* *216*, 232-235.

Gui, G.P., Wells, C.A., Browne, P.D., Yeomans, P., Jordan, S., Puddefoot, J.R., and Carpenter, R. (1995). Integrin expression in primary breast cancer and its relation to axillary nodal status. *Surgery* *117*, 102-108.

Hayashi, Y., Haimovich, B., Reszka, A., Boettiger, D., and Horwitz, A. (1990). Expression and function of chicken integrin beta 1 subunit and its cytoplasmic domain mutants in mouse NIH 3T3 cells. *J. Cell. Biol.* *110*, 175-184.

Hemler, M.E., Crouse, C., Takada, Y., and Sonnenberg, A. (1988). Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 molecules. *J. Biol. Chem.* *263*, 7660-7665.

Hynes, R.O. (1987). Integrins: A family of cell surface receptors. *Cell* *48*, 549-554.

- Hynes, R.O. (1992). Integrins: Versatility, modulation and signaling in cell adhesion. *Cell* 69, 11-25.
- Jones, J.C.R., Kurpakus, M., Cooper, H.M., and Quaranta, V. (1991). A function for the integrin  $\alpha_6\beta_4$  in the hemidesmosome. *Cell Regul.* 2, 427-438.
- Juliano, R.L. and Haskill, S. (1993). Signal transduction from the extracellular matrix. [Review]. *J. Cell. Biol.* 120, 577-585.
- Koukoulis, G.K., Virtanen, I., Korhonen, M., Laitinen, L., Quaranta, V., and Gould, V.E. (1991). Immunohistochemical localization of integrins in the normal, hyperplastic and neoplastic breast: Correlation with their functions as receptors and cell adhesion molecules. *Am. J. Pathol.* 139, 787-799.
- Kurpakus, M.A., Quaranta, V., and Jones, J.C.R. (1991). Surface relocation of  $\alpha_6\beta_4$  integrins and assembly of hemidesmosomes in an *in vitro* model of wound healing. *J. Cell Biol.* 115, 1737-1750.
- Laird, P.W., Zijderveld, A., Linders, K., Rudnicki, M.A., Jaenisch, R., and Berns, A. (1991). Simplified mammalian DNA isolation procedure. *Nucleic Acids Research* 19, 4293.
- Lin, C.S., Zhang, K., and Kramer, R. (1993).  $\alpha_6$  integrin is up-regulated in step-increments accompanying neoplastic transformation and tumorigenic conversion of human fibroblasts. *Cancer Res.* *in press*,
- Lipfert, L., Haimovich, B., Schaller, M.D., Cobb, B.S., Parsons, J.T., and Brugge, J.S. (1992). Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. *J. Cell. Biol.* 119, 905-912.
- Marcantonio, E.E., Guan, J.L., Trevithick, J.E., and Hynes, R.O. (1990). Mapping of the functional determinants of the integrin beta 1 cytoplasmic domain by site-directed mutagenesis. *Cell Regulation* 1, 597-604.
- Mareel, M., Vleminckx, K., Vermeulen, S., Gao, Y., Vakaet, L., Jr., and Bracke, M. (1992). Homotypic cell-cell adhesion molecules and tumor invasion. [Review]. *Progress in Histochemistry & Cytochemistry* 26, 95-106.
- Miettinen, M., Castello, R., Wayner, E., and Schwarting, R. (1993). Distribution of VLA integrins in solid tumors. Emergence of tumor-type-

related expression. Patterns in carcinomas and sarcomas. *Am. J. Pathol.* 142, 1009-1018.

Plopper, G.E., McNamee, H.P., Dike, L.E., Bojanowski, K., and Ingber, D.E. (1995). Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. *Molecular Biology of the Cell*. *in press*.

Quaranta, V. and Jones, J.C.R. (1991). The internal affairs of an integrin. *Trends Cell Biol.* 1, 2-4.

Ruiz, P., Dunon, D., Sonnenberg, A., and Imhof, B.A. (1993). Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for alpha6 integrins. *Cell Adh. Comm.* 1, 67-81.

Sager, R., Anisowicz, A., Neveu, M., Liang, P., and Sotiropoulou, G. (1993). Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. *FASEB J.* 7, 964-970.

Schwartz, M.A. (1992). Transmembrane signalling by integrins. *Trends in Cell Biol.* 2, 304-307.

Shaw, L.M., Lotz, M.M., and Mercurio, A.M. (1993). Inside-out integrin signaling in macrophages. Analysis of the role of the alpha 6A beta 1 and alpha 6B beta 1 integrin variants in laminin adhesion by cDNA expression in an alpha 6 integrin-deficient macrophage cell line. *Journal of Biological Chemistry* 268, 11401-11408.

Shaw, L.M. and Mercurio, A.M. (1994). Regulation of cellular interactions with laminin by integrin cytoplasmic domains: the A and B structural variants of the alpha 6 beta 1 integrin differentially modulate the adhesive strength, morphology, and migration of macrophages. *Molecular Biology of the Cell* 5, 679-690.

Solowska, J., Guan, J.L., Marcantonio, E.E., Trevithick, J.E., Buck, C.A., and HynesRO., (1989). Expression of normal and mutant avian integrin subunits in rodent cells [published erratum appears in *J Cell Biol* 1989 Oct;109(4 Pt 1):1187]. *J. Cell. Biol.* 109, 853-861.

Sonnenberg, A., Daams, H., Van Der Valk, M.A., Hilkens, J., and Hilgers, J. (1986). Development of mouse mammary gland: Identification of stages in differentiation of luminal and myoepithelial cells using monoclonal

antibodies and polyvalent antiserum against keratin. *J. Histochem. and Cytochem.* *34*, 1037-1046.

Sonnenberg, A., Modderman, P.W., and Hogervorst, F. (1988). Laminin receptor on platelets is the integrin VLA-6. *Nature* *336*, 487-489.

Sonnenberg, A., Linders, C.J., Daams, J.H., and Kennel, S.J. (1990). The alpha 6 beta 1 (VLA-6) and alpha 6 beta 4 protein complexes: tissue distribution and biochemical properties. *Journal of Cell Science* *96*, 207-217.

Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., and Yoshida, M. (1988). SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Molecular & Cellular Biology* *8*, 466-472.

Tamura, R.N., Cooper, H.M., Collo, G., and Quaranta, V. (1991). Cell-type specific integrin variants with alternative alpha chain cytoplasmic domains. *Proc. Natl. Acad. Sci. USA* *88*, 10183-10187.

Yang, J.T., Rayburn, H., and Hynes, R.O. (1993). Embryonic mesodermal defects in alpha 5 integrin-deficient mice. *Development* *119*, 1093-1105.

Yang, J.T., Rayburn, H., and Hynes, R.O. (1995). Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. *Development* *121*, 549-560.


Zachary, I. and Rozengurt, E. (1992). Focal adhesion kinase (p125FAK): A point of convergence in the action of neuropeptides, integrins and oncogenes. *Cell* *71*, 891-894.

## APPENDIX

### 1. Salary Support

The salary of Susan Domanico was supported by this grant at a rate of \$26,200.00.


2. An abstract was presented at the "Fibronectin, Integrins, and Related Molecules" Gordon Conference, February 26-March 3, 1995.




**Fig 1. Homologous recombination to create an  $\alpha 6$ -null ES cell.**

A. The targeting vector is composed of a neomycin gene, driven by the mouse phosphoglucokinase (PGK) promoter. The neo-cassette replaces a 1.2 kb *Eco RV* fragment of  $\alpha 6$  sequence, deleting the coding region for nucleotides 540-807 and 2/3 of the subsequent intron. The neo-cassette is inserted in the reverse orientation and is flanked by 2 kb and 1.8 kb of sequence homologous to the  $\alpha 6$  gene. A *Sma I* site was engineered by mutating an A to G in plasmid p209. 200 bp 5' to the *Sma I* site were deleted to create plasmid p243. This enables PCR primers to be synthesized corresponding to the deleted  $\alpha 6$  sequence. p243 has been transfected into ES1 cells and the cell line isolated, clone B5, serves as a control for the sensitivity of PCR. Clone B5 has been shown to carry only one copy of p243, as detected by Southern blot. p244 is the vector used for homologous recombination. B. PCR products generated from 19 pools of transfectants using oligos B and C were transferred to nylon and probed with  $^{32}\text{P}$  end labelled oligo E. Lane 22 represents the PCR product from the positive control cell line, clone B5. The arrow marks the anticipated 1.6 kb band. Several "faint" false positives are detectable in lanes 10 and 14. These proved to be negative at the single clone level.


### ES-1 ADHESION TO EHS LAMININ AND FIBRONECTIN



**Fig 2. ES-1 cells adhere to EHS laminin and fibronectin.** EHS laminin or bovine fibronectin, diluted in Hanks buffered saline solution (HBSS) were coated for 4 hr at 4°C. Matrix was removed and wells were blocked with 2% heat denatured BSA in HBSS, overnight at 4°C. ES-1 cells were labelled overnight with <sup>35</sup>S-methionine, harvested and plated at 5x10<sup>4</sup> cells/well. Plates were incubated 30 min at 37°C, inverted, centrifuged at 800 rpm, for 8 min. Unbound cells were washed by immersion in ice cold PBS. Bound cells were fixed and radioactivity was measured using a Molecular Dynamics phosphorimager. Shown are an average of triplicate points.




**Fig 3. ES6A.5 and ES6B.1 express similar levels fo human  $\alpha 6$ .** Cells were prepared for flow cytometry as described {682}. Anti-human  $\alpha 6$  monoclonal antibody, BQ16, was used as a 1:5000 dilution of ascites. Goat anti-mouse IgG-FITC (Sigma) was used at a dilution of 1:200. Cells were analyzed on a Becton Dickenson FACScan. ES-1 cells were stained at the negative control. ES6A.5 and ES6B.1 bind comparable amounts of BQ16 antibody.




**Fig 4. Western analysis of ES6A.5 expression of human  $\alpha 6A$ .** Detergent lysate of ES6A.5 was separated on a 4-20% SDS-PAGE gradient gel. Samples were electrophoresed under not-reducing (N) and reducing (R) conditions. Proteins were transferred to PVDF using a semi-dry transfer cell. Human  $\alpha 6A$  was detected using affinity purified 6845 at 3.7  $\mu\text{g/ml}$ . Antibody was visualized using donkey anti-rabbit-horseradish peroxidase (Amersham) and development with ECL chemiluminescence (Amersham). Molecular weight standards are marked on the right and the unreduced heavy chain (H) and reduced light chain (L) of  $\alpha 6$  are indicated with arrows.

ES6A.5 and ES6B.1 bind Laminin at comparable levels




**Fig 5. ES6A.5 and ES6B.1 cells bind EHS laminin at comparable levels.** EHS laminin, bovine fibronectin, and rat collagen were diluted to 40 µg/ml in Hanks buffered saline solution (HBSS) and coated on to polystyrene for 4 hr at 4°C. Matrix was removed and wells were blocked with 2% heat denatured BSA in HBSS, overnight at 4°C. ES-1, ES6A.5 and ES6B.1 cells were labelled overnight with <sup>35</sup>S-methionine, harvested and plated at 5x10<sup>4</sup> cells/well. Plates were incubated 30 min at 37°C, inverted, centrifuged at 800 rpm, for 8 min. Unbound cells were washed by immersion in ice cold PBS. Bound cells were fixed and radioactivity was measured using a Molecular Dynamics phosphorimager. Shown are an average of triplicate points.


ES-1



ES-6A.5




ES-6B.1




**Fig 6.** ES6A.5 cells have a different morphology than ES-1 and ES6B.1 cells. ES-1 (top panel), ES6A.5 (middle panel), and ES6B.1 (bottom panel) were grown on 0.1% gelatin until confluency. Shown are representative fields of each cell line. Photographs were taken on an Olympus phase contrast microscope at 20x magnification. The ES-1 and ES6B.1 cells grew in smooth-edged islands, characteristic of ES cells, while the ES6A.5 cells grew in looser islands, exhibited more jagged edges, and extended more processes.

## ES6A.5 cells migrate more than ES-1 and ES6B.1




**Fig 7. ES6A.5 cells are more migratory than ES-1 or ES6B.1 cells.** Transwell membranes were coated with 40  $\mu\text{g/ml}$  EHS laminin or bovine fibronectin in HBSS for 4 hr at 37°C. Matrix was removed by aspiration, and  $6 \times 10^4$  cells in 0.3 ml DMEM + sodium pyruvate, glutamine and LIF (C-DMEM) were added to the top chamber. C-DMEM (0.5ml) was added to the bottom chamber. Cells were incubated 18 hr at 37°C. Media was aspirated, and the cells on the membranes were fixed and stained. The top of the membranes were swabbed with a cotton applicator to remove cells that did not migrate through the membrane. Membranes were cut out, mounted and cells were counted using a 40x objective. All cells within a field were counted.

## ES6A.5 migration is not inhibited by RGD



**Fig 8. ES6A.5 cell migration on fibronectin is not RGD dependent.** Transwell membranes were coated with 40  $\mu\text{g/ml}$  EHS laminin or bovine fibronectin in HBSS for 4 hr at 37°C. Matrix was removed by aspiration, and  $6 \times 10^4$  cells in C-DMEM with or without 268  $\mu\text{M}$  RGD peptide were added to the top chamber. C-DMEM with or without 268  $\mu\text{M}$  RGD peptide (0.5ml) was added to the bottom chamber. Cells were incubated 18 hr at 37°C. Media was aspirated, and the cells on the membranes were fixed and stained. The top of the membranes were swabbed with a cotton applicator to remove cells that did not migrate through the membrane. Membranes were cut out, mounted and cells were counted using a 40x objective. All cells within a field were counted. As control for RGD inhibition, M21 cells did not migrate on fibronectin in the presence of RGD. There was no effect of RGD on the migration of ES6A.5 cells.

## ES6A.5 cells migrate through gelatin-coated membranes



**Fig 9. ES6A.5 cells migrate through gelatin-coated Transwell membranes.** Transwell membranes were coated with 0.1% denatured gelatin for 4 hr at 37°C. Gelatin was removed by aspiration, and  $6 \times 10^4$  cells in 0.3 ml DMEM + sodium pyruvate, glutamine and LIF (C-DMEM) were added to the top chamber. C-DMEM (0.5ml) was added to the bottom chamber. Cells were incubated 18 hr at 37°C. Media was aspirated, and the cells on the membranes were fixed and stained. The top of the membranes were swabbed with a cotton applicator to remove cells that did not migrate through the membrane. Membranes were cut out, mounted and cells were counted using a 40x objective. All cells within a field were counted. ES6A.5 cells migrated through the Transwell membrane, while ES-1 and ES6B.1 cells did not.